If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The team discovered that Penicillium extract killed several types of bacteria. Gardner and Orr-Ewing tested it against gonococci (against which it was most effective), meningococci, streptococci, staphylococci, anthrax bacteria, Actinomyces and the organisms that caused tetanus and gangrene. Florey and Jennings experimented on rats, mice, rabbits and cats in which penicillin was administered in various ways, and found no evidence of toxicity. On 25 May 1940, Florey injected eight mice with a virulent strain of streptococcus, and then four of them with penicillin. A day later all four of the untreated mice were dead, but all of the treated ones were still alive, although one died two days later. Over the following weeks Jennings and Florey repeated the experiment with ever-larger batches of mice, and with different bacteria. They found that penicillin was also effective against staphylococci and the bacteria that cause gangrene. They published their findings in The Lancet on 24 August 1940. Florey reminded his staff that as promising as their results were, a man weighed 3,000 times as much as a mouse. In February 1941, Florey and Chain treated their first patient, Albert Alexander, who had had a small sore at the corner of his mouth, which then spread, leading to a severe facial infection involving streptococci and staphylococci. His whole face, eyes and scalp were swollen to the extent that he had had an eye removed to relieve the pain. Within a day of being given penicillin, he started to recover.
Thorium and protactinium, but not uranium compounds, are poorly soluble in aqueous solutions and precipitate into sediments; the precipitation rate is faster for thorium than for protactinium. The concentration analysis for both protactinium-231 (half-life 32,760 years) and 230Th (half-life 75,380 years) improves measurement accuracy compared to when only one isotope is measured; this double-isotope method is also weakly sensitive to inhomogeneities in the spatial distribution of the isotopes and to variations in their precipitation rate.
Zopiclone, sold under the brand name Imovane among others, is a benzodiazepine-like drug (Z-drug) used as a pharmaceutical treatment for insomnia. While molecularly distinct from benzodiazepine drugs, zopiclone's mechanism of action is similar: it increases the transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via positive allosteric modulation at GABAA neurons. Zopiclone is considered a sedative and CNS depressant. Zopiclone and other benzodiazepine-like drugs like zaleplon and zolpidem are addictive. Within days to weeks, the body can become accustomed to the effects of zopiclone. The risk of developing tolerance with benzodiazepine-like drugs is comparable to benzodiazepines. When the dose is then reduced or the drug is abruptly stopped, withdrawal symptoms similar to those of benzodiazepine withdrawal may result. Benzodiazepine-like drugs decrease sleep latency by 10 to 20 minutes. However, no benzodiazepine-like drug has shown clinically significant increase in total sleep time. Zopiclone is recommended only to be taken at the lowest effective dose, with a duration of 2–3 weeks, for short-term insomnia. Use of zopiclone more than 4 weeks is not recommended. It is dangerous to take with benzodiazepines, sedatives, alcohol or other drugs affecting the central nervous system. In the United States, zopiclone is not commercially available, although its active stereoisomer, eszopiclone, is.
John Gross FRSL (12 March 1935 – 10 January 2011); editor of The Times Literary Supplement, senior book editor and book critic on The New York Times, theatre critic for The Sunday Telegraph; assistant editor on Encounter; literary editor of The New Statesman and Spectator; author of The Rise and Fall of the Man of Letters, James Joyce, Shylock: Four Hundred Years in the Life of a Legend; works as editor and anthologist include After Shakespeare: Writing inspired by the world's greatest author, The Oxford Book of Aphorisms, The Oxford Book of Essays, The Oxford Book of Comic Verse, The New Oxford Book of English Prose, The New Oxford Book of Literary Anecdotes, The Modern Movement, Dickens and the Twentieth Century, and The Oxford Book of Parodies; was trustee of London's National Portrait Gallery; served on the English Heritage advisory committee on blue plaques; advised British government on the award of public honours He served as chairman of the judges of the Booker Prize,; member of The Literary Society; director of Times Newspaper holdings, the publishers of The Times and The Sunday Times; married to Miriam Gross, literary editor; had two children, Tom Gross and Susanna Gross.
Sources: en.wikipedia.org
Regioselectivity: The key feature of native chemical ligation of unprotected peptides is the reversibility of the first step, the thiol(ate)–thioester exchange reaction. Native chemical ligation is exquisitely regioselective because that thiol(ate)–thioester exchange step is freely reversible in the presence of an added arylthiol catalyst. The high yields of final ligation product obtained, even in the presence of internal Cys residues in either/both segments, is the result of the irreversibility of the second (S-to-N acyl shift) amide-forming step under the reaction conditions used.
Soldiers returning home from the Crusades in the 11th to 13th century brought opium with them. Opium is said to have been used for recreational purposes from the 14th century onwards in Muslim societies. Ottoman and European testimonies confirm that from the 16th to the 19th centuries Anatolian opium was eaten in Constantinople as much as it was exported to Europe. In 1573, for instance, a Venetian visitor to the Ottoman Empire observed many of the Turkish natives of Constantinople regularly drank a "certain black water made with opium" that makes them feel good, but to which they become so addicted, if they try to go without, they will "quickly die". From drinking it, dervishes claimed the drugs bestowed them with visionary glimpses of future happiness. Indeed, the Ottoman Empire supplied the West with opium long before China and India. Extensive textual and pictorial sources also show that poppy cultivation and opium consumption were widespread in Safavid Iran and Mughal India.
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme. It is manufactured by Shire plc. The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature. Velaglucerase alfa was approved for medical use in the United States in February 2010, and in the European Union in August 2010.
Sources: en.wikipedia.org
=== Pharmacokinetics === Nicomorphine is rapidly metabolized when administered by the I.V. route, having a half-life of 3 minutes, into morphine and 6-nicotinoylmorphine, the secondary active metabolite. Half lives of the metabolites were 3–15 minutes for the nicotinoyl metabolite, and 135–190 minutes for morphine. Via the epidural route, a much slower release from epidural space occurs and nicomorphine remains detectable for 1.5 hours or so, and has a longer effect of 18.2 +/- 10.1 hours due to slower release of the active metabolites, morphine and 6-nicotinoylmorphine. Half lives for those compounds is listed in the IV route. Pharmacokinetics via the rectal route differ, and change metabolism. Eight minutes after administration, morphine appeared rapidly, and had a half life of 1.48 +/- 0.48h. This was in turn metabolized to morphine-3- and morphine-6-glucoranides after another 12 minutes, which had similar half-lives to one-another, at about 2.8h. No 6-mononicotinoylmorphine was found, and bioavailability of morphine and metabolic actives was 88%. No remaining nicomorphine was found in urine.
=== Container Freight Stations (CFS) === GDL operates Container Freight Stations, located at major Indian ports such as Navi Mumbai, Chennai, Visakhapatanam, and Kochi. The stations offer container yards, general warehousing, bonded warehousing, empty handling and RFID technologies used for container tracking. GDL also has its own dedicated fleet of over 25 rakes and 265 trailers for first and last mile connectivity.
==== Moisture content differences ==== The chemical potential is explained here since it is the true driving force for the transport of water in both liquid and vapour phases in wood. The Gibbs free energy per mole of substance is usually expressed as the chemical potential of that substance. The chemical potential of water in unsaturated air or wood below the fibre saturation point influences the drying of wood. Equilibrium will occur at the equilibrium moisture content (as defined earlier) of wood when the chemical potential of water in the wood becomes equal to that in the surrounding air. The chemical potential of sorbed water is a function of wood moisture content. Therefore, a gradient of wood moisture content (between surface and centre), or more specifically of water activity, is accompanied by a gradient of chemical potential under isothermal conditions. Moisture will redistribute itself throughout the wood until its chemical potential is uniform throughout, resulting in a zero potential gradient at equilibrium. The flux of moisture attempting to achieve the equilibrium state is assumed to be proportional to the difference in its chemical potential, and inversely proportional to the path length over which the potential difference acts. The gradient in chemical potential is related to the moisture content gradient as explained in above equations. The diffusion model using the moisture content gradient as a driving force was applied successfully by Wu (1989) and Doe et al. (1994).
Other types of car windows can reduce transmission of UV that is greater than 335 nm. Fused quartz, depending on quality, can be transparent even to vacuum UV wavelengths. Crystalline quartz and some crystals such as CaF2 and MgF2 transmit well down to 150 nm or 160 nm wavelengths. Wood's glass is a deep violet-blue barium-sodium silicate glass with about 9% nickel(II) oxide developed during World War I to block visible light for covert communications. It allows both infrared daylight and ultraviolet night-time communications by being transparent between 320 nm and 400 nm and also the longer infrared and far-red light. Its maximum UV transmission is at 365 nm, one of the wavelengths of mercury lamps.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.